A Randomized, Double-Blinded, Crossover Pilot Study Assessing the Effect of Nabilone on Spasticity in Persons With Spinal Cord Injury

Archives of Physical Medicine and Rehabilitation

Volumn 91, Issue 5, 2010, Pages 703-707

  Pooyania, Sepideh ^a   Ethans, Karen ^a   Szturm, Tony ^a   Casey, Alan ^a   Perry, Daryl ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cannabinoids; Muscle spasticity; Nabilone name of substance ; Rehabilitation; Spinal cord injuries

Indexed keywords

NABILONE; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; HUMAN; MALE; MUSCLE FUNCTION; OUTCOME ASSESSMENT; PARAPLEGIA; QUADRIPLEGIA; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; SPINAL CORD INJURY; TREATMENT RESPONSE; VERTIGO; VISUAL ANALOG SCALE; XEROSTOMIA;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MUSCLE SPASTICITY; PARAPLEGIA; PILOT PROJECTS; QUADRIPLEGIA; SPINAL CORD INJURIES; TETRAHYDROCANNABINOL;

EID: 77951262920     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2009.12.025     Document Type: Article

References (26)

1. DeLisa J.A., Gans B.M., and Bockenek W.L. Rehabilitation medicine: principles and practice. 4th ed. (2005), Lippincott-Raven, Philadelphia
2. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol Ther 95 (2002) 165-174
3. Young R.R. Spasticity a review. Neurology 44 11 Suppl 9 (1994) S12-S20
4. Maynard F.M., Karunas R.S., and Waring W.P. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil 71 (1990) 566-569
5. Walter J.S., Sacks J., Othman R., et al. A database of self-reported secondary medical problems among VA spinal cord injury patients: its role in clinical care and management. J Rehabil Res Dev 39 (2002) 53-61
6. Johnson R.L., Gerhart K.A., McCray J., Menconi J.C., and Whiteneck G.G. Secondary conditions following spinal cord injury in a population based sample. Spinal Cord 36 (1998) 45-50
7. Pertwee R.G. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed 6 Suppl 3 (1999) 12-15
8. Dunn M., and Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 12 (1974) 175
9. Malec J., Harvey R.F., and Cayner J.J. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil 63 (1982) 116-118
10. Cansroe P., Musty R., Rein J., Tillery W., and Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38 (1997) 44-48
11. Maurer M., Henn V., Dittrich A., and Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesics effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240 (1990) 1-4
12. Brenneisen R., Egli A., Elsohly M.A., Henn V., and Spiess Y. The effect of orally and rectally administrated delta 9-tetrahydrocannabinole on spasticity, a pilot study with 2 patients. Int J Clin Pharmacol Ther 34 (1996) 446-452
13. Zajicek J., Fox P., Sanders H., Wright D., et al., UK MS research group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo-controlled trial. Lancet 362 (2003) 1517-1526
14. Ashworth B. Preliminary trial of carisolrodol in multiple sclerosis. Practitioner 192 (1964) 540-542
15. Bohannon R.W., and Smith M.B. Inter-rater reliability of a modified Ashworth Scale of muscle spasticity. Phys Ther 67 (1987) 206-207
16. Johnson G.R. Outcome measures of spasticity. Eur J Neurol 9 Suppl 1 (2002) 10-16
17. Penn R.D. Intrathecal baclofen for severe spasticity. Ann N Y Acad Sci 531 (1988) 157-166
18. Priebe M.M., Sherwood A.M., Thornby J.I., Kharas N.F., and Markowski J. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 77 (1996) 713-716
19. Stewart J.E., Barbeau H., and Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Can J Neurol Sci 18 (1991) 321-332
20. Skold C. Spasticity in spinal cord injury: self- and clinically rated intrinsic fluctuations and intervention-induced changes. Arch Phys Med Rehabil 81 (2000) 144-149
21. Wartenberg R. Pendulousness of the legs as a diagnostic test. Neurology 1 (1951) 18-24
22. Fowler E.G., Nwigwe A.I., and Ho T.W. Sensitivity of the pendulum test for assessing spasticity in persons with cerebral palsy. Dev Med Child Neurol 42 (2000) 182-189
23. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 57 (1995) 289-300
24. Strassburger K., and Bretz F. Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni-based closed tests. Stat Med 27 (2008) 4914-4927
25. 9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 45 (2007) 551-562
26. Kogel R.W., Johnson P.B., Chintam R., Robinson C.J., and Nemchausky B.A. Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative. Am J Ther 2 (1995) 799-805